Tamsulosin Hydrochloride Archives - PMC Herbals

Contiflo Icon 0.4 Mg Tablet PR

Joyce Bhatia — Tue, 21 Apr 2026 06:55:49 +0000

Contiflo Icon 0.4 Mg Tablet PR (Tamsulosin Hydrochloride)

Contiflo Icon 0.4 Mg Tablet PR is a high-potency pharmacological intervention containing Tamsulosin Hydrochloride, a selective alpha-1 adrenoceptor antagonist specifically engineered for the clinical management of functional symptoms associated with Benign Prostatic Hyperplasia (BPH). Utilizing a unique “Prolonged-Release” (PR) delivery system, this formulation works by concurrently modulating the smooth muscle tension in the prostatic urethra and the bladder neck. By neutralizing the biochemical triggers of localized muscular constriction and facilitating the organized relaxation of the prostate gland tissues, Contiflo Icon effectively promotes an immediate increase in urinary flow rates and a reduction in obstructive symptoms. This targeted biochemical action provides a decisive therapeutic response by reinforcing the structural uniformity of the urinary passage and promoting a stable, physiological recovery from lower urinary tract stressors.

Key Features

Specifically formulated with Tamsulosin to target the alpha-1A and alpha-1D receptors located within the prostatic and bladder smooth muscle.
Clinically recognized for its role in facilitating the natural optimization of urinary flow and reducing post-void residual volume.
Specifically engineered to reach therapeutic levels steadily over a 24-hour period, ensuring a robust defense against nocturnal frequency.
Acts as a functional catalyst to stabilize the bladder function and support the reduction of urgency and hesitancy.
Formulated to address localized BPH symptoms with minimal impact on systemic blood pressure compared to non-selective antagonists.

Key Ingredients

Tamsulosin Hydrochloride (0.4 mg)
Hypromellose (HPMC)
Microcrystalline Cellulose
Magnesium Stearate

Precautions

This is a high-potency urological medication. Use must be strictly dictated by a healthcare professional after a formal clinical diagnosis of BPH.
Be advised that temporary dizziness or postural hypotension may occur; exercise caution when rising from a seated or lying position.
Patients scheduled for cataract or glaucoma surgery must inform their ophthalmic surgeon of Contiflo Icon use to prevent Intraoperative Floppy Iris Syndrome (IFIS).
Consult with a specialist regarding potential interactions with other alpha-blockers or phosphodiesterase-5 (PDE5) inhibitors.
This formulation is specifically indicated for male physiological requirements and is not intended for use in pediatric or female patient populations.
Keep the blister pack tightly sealed and store in a cool, dry place (below 25°C). Protect from direct light to maintain the molecular stability of the active constituent.

How to Use

The tablet should be swallowed whole with a glass of water. Do not crush, break, or chew the tablet to ensure the intended prolonged-release delivery.
A single 0.4 mg tablet constitutes the standard daily therapeutic dose, unless otherwise specifically directed by a urologist.
For optimal clinical results, administration should occur at the same time each day, preferably following the same meal (typically breakfast or dinner).
Ensure consistent daily intake to maintain stable plasma concentrations and ensure the continuous relaxation of the prostatic smooth muscle.
Use as a standalone urological treatment or as part of a comprehensive combination therapy for BPH as dictated by clinical requirements.
Maintain a regular schedule to document visible improvements in urinary flow and the reduction of obstructive symptoms over a sustained period.

Legal Disclaimer: Contiflo Icon 0.4 Mg Tablet PR is a specialized pharmacological intervention for BPH symptoms. Individual results vary based on the patient’s baseline prostatic volume and physiological response. This product does not prevent prostate cancer and should be used only after appropriate clinical screening. This information is for educational purposes and is not a substitute for professional medical consultation or a formal clinical diagnosis.

The post Contiflo Icon 0.4 Mg Tablet PR appeared first on PMC Herbals.

Veltam Plus Tablet MR

Joyce Bhatia — Tue, 21 Apr 2026 06:20:39 +0000

Veltam Plus Tablet MR (Tamsulosin Hydrochloride & Dutasteride)

Veltam Plus Tablet MR is a high-potency pharmacological intervention specifically engineered for the clinical management of moderate-to-severe symptomatic Benign Prostatic Hyperplasia (BPH). Utilizing a unique “Dual-Action” delivery system, this formulation works by concurrently modulating the smooth muscle tension in the urinary passage and reinforcing the reduction of the physical volume of the prostate gland. By combining an alpha-1 adrenoceptor antagonist with a 5-alpha reductase inhibitor, Veltam Plus effectively promotes an immediate increase in urinary flow and facilitates the organized suppression of dihydrotestosterone (DHT) levels. This targeted biochemical action provides a decisive therapeutic response by reinforcing the structural uniformity of the prostatic tissues and promoting a stable, physiological recovery from obstructive urological stressors.

Key Features

Specifically formulated with Tamsulosin and Dutasteride to target both the dynamic and static components of BPH.
Clinically recognized for its role in facilitating the natural optimization of hormone-driven prostatic growth cycles.
Specifically engineered to reach therapeutic levels steadily, ensuring a robust defense against nocturnal frequency and urinary urgency.
Acts as a functional catalyst to stabilize the bladder neck function and support the long-term reduction of prostate volume.
Formulated to address the risk of acute urinary retention and the potential requirement for urological surgery.

Key Ingredients

Tamsulosin Hydrochloride (0.4 mg)
Dutasteride (0.5 mg)
Microcrystalline Cellulose
Magnesium Stearate

Precautions

This is a high-potency urological medication. Use must be strictly dictated by a healthcare professional after a formal clinical diagnosis and PSA screening.
Patients utilizing this formulation must not donate blood until at least 6 months after the final dose to prevent exposure to pregnant recipients.
Inform your surgeon of Veltam Plus use prior to cataract or glaucoma procedures to manage the risk of Intraoperative Floppy Iris Syndrome (IFIS).
Because Dutasteride can be absorbed through the skin, women who are pregnant or may become pregnant must not handle the tablets.
Be advised that temporary dizziness may occur; exercise caution when transitioning between seated and standing positions.
Keep the blister pack tightly sealed and store in a cool, dry place (below 25°C). Protect from direct light to maintain the molecular stability of the active constituents.

How to Use

The tablet should be swallowed whole with a glass of water. Do not crush or chew the tablet to ensure the intended modified-release delivery.
A single tablet constitutes the standard daily therapeutic dose, unless otherwise specifically directed by a urologist.
For optimal clinical results, administration should occur approximately 30 minutes following the same meal each day.
Ensure consistent daily intake to maintain stable plasma concentrations and facilitate the long-term reduction of prostatic volume.
Use as a standalone urological treatment for advanced BPH as dictated by your clinical restoration regimen.
Maintain a regular application schedule for a minimum of 3 to 6 months to document visible improvements in urinary flow and glandular reduction.

Legal Disclaimer: Veltam Plus Tablet MR is a specialized pharmacological intervention. Individual results vary based on the patient’s baseline prostatic volume and physiological response. This product is intended for male physiological requirements only. This information is for educational purposes and is not a substitute for professional medical consultation or a formal clinical diagnosis.

The post Veltam Plus Tablet MR appeared first on PMC Herbals.

Urimax 0.4 Mg

Joyce Bhatia — Tue, 21 Apr 2026 06:07:56 +0000

Urimax 0.4 Mg (Tamsulosin Hydrochloride)

Urimax 0.4 Mg is a high-potency pharmacological intervention containing Tamsulosin Hydrochloride, a selective alpha-1 adrenoceptor antagonist specifically engineered for the clinical management of the functional symptoms associated with Benign Prostatic Hyperplasia (BPH). Utilizing a unique “Uro-Selective” delivery system, this formulation works by concurrently modulating the smooth muscle tension in the prostatic urethra and the bladder neck. By neutralizing the biochemical triggers of localized muscular constriction and facilitating the organized relaxation of the prostate gland tissues, Urimax effectively promotes an immediate increase in urinary flow rates and a reduction in obstructive symptoms. This targeted biochemical action provides a decisive therapeutic response by reinforcing the structural uniformity of the urinary passage and promoting a stable, physiological recovery from lower urinary tract stressors.

Key Features

Specifically formulated with Tamsulosin to target the alpha-1A and alpha-1D receptors located within the prostatic and bladder smooth muscle.
Clinically recognized for its role in facilitating the natural optimization of urinary flow and reducing post-void residual volume.
Specifically engineered to reach therapeutic levels steadily over a 24-hour period, ensuring a robust defense against nocturnal frequency.
Acts as a functional catalyst to stabilize the bladder function and support the reduction of urgency and hesitancy.
Formulated to address localized BPH symptoms with minimal impact on systemic blood pressure compared to non-selective antagonists.

Key Ingredients

Tamsulosin Hydrochloride (0.4 mg)
Microcrystalline Cellulose
Methacrylic Acid Copolymer
Magnesium Stearate

Precautions

This is a high-potency urological medication. Use must be strictly dictated by a healthcare professional after a formal clinical diagnosis of BPH.
Be advised that temporary dizziness or syncope (fainting) may occur following the initial dose or dosage adjustments; exercise caution when rising from a seated position.
Patients scheduled for cataract or glaucoma surgery must inform their ophthalmic surgeon of Urimax use to prevent Intraoperative Floppy Iris Syndrome (IFIS).
Consult with a specialist regarding potential interactions with other alpha-blockers or phosphodiesterase-5 (PDE5) inhibitors.
This formulation is specifically indicated for male physiological requirements and is not intended for use in pediatric or female patient populations.
Keep the blister pack tightly sealed and store in a cool, dry place (below 25°C). Protect from direct light to maintain the molecular stability of the active constituent.

How to Use

The capsule should be swallowed whole with a glass of water. Do not crush or chew the capsule to ensure the intended modified-release delivery.
A single 0.4 mg capsule constitutes the standard daily therapeutic dose, unless otherwise specifically directed by a urologist.
For optimal clinical results, administration should occur approximately 30 minutes following the same meal each day (typically breakfast).
Ensure consistent daily intake to maintain stable plasma concentrations and ensure the continuous relaxation of the prostatic smooth muscle.
Use as a standalone urological treatment or as part of a comprehensive combination therapy for BPH as dictated by clinical requirements.
Maintain a regular application schedule to document visible improvements in urinary flow and the reduction of obstructive symptoms over a sustained period.

Legal Disclaimer: Urimax 0.4 Mg is a specialized pharmacological intervention for BPH symptoms. Individual results vary based on the patient’s baseline prostatic volume and physiological response. This product does not prevent prostate cancer and should be used only after appropriate clinical screening. This information is for educational purposes and is not a substitute for professional medical consultation or a formal clinical diagnosis.

The post Urimax 0.4 Mg appeared first on PMC Herbals.